Biohaven Bets on “Better Weight Loss,” Not Just Mo...
Category : Clinical Trial Update 23 March 2026The obesity drug race is entering its next phase. Biohaven Ltd. has completed enrollment for a Phase...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
GSK Scores a First: FDA Approves Lynavoy for Chron...
Category : Approval/Launch 23 March 2026Some conditions are overlooked—not because they’re rare, but because they’re misun...
Eris Lifesciences Disrupts the GLP-1 Market with ₹...
Category : ODD/BTA/FTA Status 23 March 2026The semaglutide price war in India just hit a new low. Eris Lifesciences Limited has launched its ge...
Alzheimer’s Drug LEQEMBI Shows Strong Real-World P...
Category : Clinical Trial Update 23 March 2026In Alzheimer’s treatment, efficacy is only half the story. The other half? Do patients actuall...
Sobi presents positive results from EMBRACE phase...
Category : Clinical Trial Update 20 March 2026Sobi, a global biopharma company unlocking the potential of breakthrough innovations, transforming e...
Latest Newsletter Post
-
Alzheimer’s Drug LEQEMBI Shows Stro..
23 March 2026
-
Eris Lifesciences Disrupts the GLP-..
23 March 2026
-
GSK Scores a First: FDA Approves Ly..
23 March 2026
-
Biohaven Bets on “Better Weight Los..
23 March 2026
-
US FDA grants Breakthrough Therapy..
20 March 2026
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com